Open AccessEarly Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
Author(s) -
Anne Jacobson
Publication year - 2022
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1093/oncolo/oyac016
Subject(s) - palbociclib , fulvestrant , medicine , metastatic breast cancer , estrogen receptor , oncology , aromatase inhibitor , aromatase , breast cancer , cancer , estrogen
For patients with estrogen receptor-positive metastatic breast cancer who are treated with palbociclib plus an aromatase inhibitor, the strategy of switching to palbociclib plus fulvestrant upon detection of a resistance mutation more than doubled progression-free survival, according to results from the phase III PADA-1 trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom